Update of tnf-alpha antagonists and cardiovascular disease in rheumatoid arthritis
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Tumor necrosis factor-á (TNF-á) antagonists were unexpectedly found to have no beneficial effects in moderate-to-severe heart failure in two large randomized clinical trials. In certain doses, the agents were found to be harmful. These results have important implications for rheumatoid arthritis (RA). Patients with the disease have an increased risk for developing cardiovascular co-morbidity, including heart failure. Because of the beneficial effect of the TNF-á antagonists in the management of RA, these agents have gained widespread use. Rheumatologists and other physicians who provide care for RA are thus likely to encounter candidates for anti-TNF-á therapy who have overt or subclinical heart failure. Although data are currently not sufficient to support evidence-based recommendations, it is possible to make reasonable suggestions to guide clinical practice.
- Hochberg MC, Lebwohl MG, Plevy SE, et al.: The benefit/risk profile of TNF-blocking agents: findings of a consensus panel. Semin Arthritis Rheum 2005, 34:819–836. CrossRef
- Hyrich KL, Silman AJ, Watson KD, Symmons DP: Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety. Ann Rheum Dis 2004, 63:1538–1543. CrossRef
- Khanna D, McMahon M, Furst DE: Anti-tumor necrosis factor alpha therapy and heart failure: what have we learned and where do we go from here? Arthritis Rheum 2004, 50:1040–1050. This is a thorough review of the information on the subject that was available at the time. It includes discussions of the rationale for using TNF-á antagonists in heart failure, results of controlled trials, and reasonable suggestions for clinical management. CrossRef
- del Rincón I, Williams K, Stern MP, et al.: High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001, 44:2737–2745. CrossRef
- Solomon DH, Karlson EW, Rimm EB, et al.: Cardiovascular morbidity and mortality in women diagnosed with rheuma-toid arthritis. Circulation 2003, 107:1303–1307. CrossRef
- Wolfe F, Freundlich B, Straus WL: Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis. J Rheumatol 2003, 30:36–40.
- Maradit-Kremers H, Crowson CS, Nicola PJ, et al.: Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 2005, 52:402–411. Additional analyses of data from the Rochester Epidemiology Project. A cohort of RA patients who received care in Olmsted County, Minne-sota was found to have an increased rate for coronary heart disease and sudden death. CrossRef
- Watson D, Rhodes T, Guess H: All-cause mortality and vascular events among patients with RA, OA, or no arthritis in the UK General Practice Research Database. J Rheumatol 2003, 30:1196–1202.
- Sihvonen S, Korpela M, Laippala P, et al.: Death rates and causes of death in patients with rheumatoid arthritis: a population-based study. Scand J Rheumatol 2004, 33:221–227. CrossRef
- Wallberg-Jonsson S, Johansson H, Ohman ML, et al.: Extent of inflammation predicts cardiovascular disease and over-all mortality in seropositive rheumatoid arthritis: a retro-spective cohort study from disease onset. J Rheumatol 1999, 26:2562–2571.
- Maradit-Kremers H, Nicola PJ, Crowson CS, et al.: Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 2005, 52:722–732. Additional analyses of data from the Rochester Epidemiology Project. A cohort of RA patients who received care in Olmsted County. Excess mortality due to cardiovascular causes is related to systemic inflammation. CrossRef
- del Rincón I, O’Leary DH, Haas RW, Escalante A: An estimate of the relative contribution of CV risk factors and manifesta-tions of rheumatoid arthritis to carotid atherosclerosis [abstract]. Arthritis Rheum 2004, 50(Suppl 9):S170-S315.
- Solomon DH, Curhan GC, Rimm EB, et al.: Cardiovascular risk factors in women with and without rheumatoid arthritis. Arthritis Rheum 2004, 50:3444–3449. CrossRef
- del Rincón I, Williams K, Stern MP, et al.: Association between carotid atherosclerosis and markers of inflammation in rheu-matoid arthritis patients and healthy subjects. Arthritis Rheum 2003, 48:1833–1840. CrossRef
- Wei L, MacDonald TM, Walker BR: Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med 2004, 141:764–770. Glucocorticoid exposure associated with increased cardiovascular event rate in a large database of patients from the United Kingdom’s National Health Service.
- del Rincón I, O’Leary DH, Haas RW, Escalante A: Effect of glucocorticoids on the arteries in rheumatoid arthritis. Arthritis Rheum 2004, 50:3813–3822. Cumulative dose of glucocorticoids was associated with increased frequency of carotid plaque and lower limb arterial incompressibility in an RA cohort. CrossRef
- Solomon DH, Schneeweiss S, Glynn RJ, et al.: Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 2004, 109:2068–2073. CrossRef
- Levine B, Kalman J, Mayer L, et al.: Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990, 323:236–241. CrossRef
- Bozkurt B, Kribbs SB, Clubb FJ Jr, et al.: Pathophysiologically relevant concentrations of tumor necrosis factor-alpha pro-mote progressive left ventricular dysfunction and remodeling in rats. Circulation 1998, 97:1382–1391.
- Yokoyama T, Vaca L, Rossen RD, et al.: Cellular basis for the negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian heart. J Clin Invest 1993, 92:2303–2312. CrossRef
- Torre-Amione G, Kapadia S, Lee J, et al.: Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation 1996, 93:704–711.
- Nicola PJ, Maradit-Kremers H, Roger VL, et al.: The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years. Arthritis Rheum 2005, 52:412–420. Additional analyses of data from the Rochester Epidemiology Project. A cohort of RA patients who received care in Olmsted County, was found to have an increased frequency of heart failure. CrossRef
- Fichtlscherer S, Rossig L, Breuer S, et al.: Tumor necrosis factor antagonism with etanercept improves systemic endothelial vasoreactivity in patients with advanced heart failure. Circulation 2001, 104:3023–3025.
- Hurlimann D, Forster A, Noll G, et al.: Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 2002, 106:2184–2187. CrossRef
- Gonzalez-Juanatey C, Testa A, Garcia-Castelo A, et al.: Active but transient improvement of endothelial function in rheu-matoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor alpha antibody. Arthritis Rheum 2004, 51:447–450. CrossRef
- Irace C, Mancuso G, Fiaschi E, et al.: Effect of anti TNFalpha therapy on arterial diameter and wall shear stress and HDL cholesterol. Atherosclerosis 2004, 177:113–118. CrossRef
- Hotamisligil GS: The role of TNFalpha and TNF receptors in obesity and insulin resistance. J Intern Med 1999, 245:621–625. CrossRef
- Greenberg AS, McDaniel ML: Identifying the links between obesity, insulin resistance and beta-cell function: potential role of adipocyte-derived cytokines in the pathogenesis of type 2 diabetes. Eur J Clin Invest 2002, 32(Suppl 3):24–34. CrossRef
- Yazdani-Biuki B, Stelzl H, Brezinchek HP, et al.: Improvement of insulin sensitivity in insulin resistant subjects during pro-longed treatment with the anti-TNF-_ antibody infliximab. Eur J Clin Invest 2004, 34:641–642. CrossRef
- Popa C, Netea MG, Radstake T, et al.: Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis. Ann Rheum Dis 2005, 64:303–335. CrossRef
- Cauza C, Cauza K, Hanusch-Enserer U, et al.: Intravenous TNF-_ antibody therapy leads to elevated triglyceride and reduced HDL-cholesterol levels in patients with rheumatoid and psori-atic arthritis. Wien Klin Wochenschr 2002, 114:1004–1007.
- Calabresi L, Rossoni G, Gomaraschi M, et al.: High-density lipo-proteins protect isolated rat hearts from ischemia-reperfusion injury by reducing cardiac tumor necrosis factor-alpha content and enhancing prostaglandin release. Circ Res 2003, 92:330–337. CrossRef
- Chung ES, Packer M, Lo KH, et al.: Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric mono-clonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003, 107:3133–3140. Randomized clinical trials of infliximab in moderate-to-severe heart failure revealed no benefit. Patients who received 10 mg/kg experi-enced a higher risk for death or hospitalization for heart failure. CrossRef
- Mann DL, McMurray JJ, Packer M, et al.: Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004, 109:1594–1602. Randomized clinical trial of etanercept in moderate to severe heart failure revealed not benefit. The study had to be stopped prematurely due to lack of benefit in the treatment group. CrossRef
- Remicade [package insert]. Malvern, PA: Centocor, Inc.; 2005.
- de’ Clari F, Salani I, Safwan E, Giannacco A Sudden death in a patient without heart failure after a single infusion of 200 mg infliximab: does TNF-alpha have protective effects on the failing heart, or does infliximab have direct harmful cardio-vascular effects? Circulation 2002, 105:E183. CrossRef
- Kwon HJ, Cote TR, Cuffe MS, et al.: Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 2003, 138:807–811.
- Wolfe F, Michaud K: Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am J Med 2004, 116:305–311. Non-randomized study showing a reduced rate of heart failure among patients who received TNF-á antagonists. CrossRef
- Bernatsky S, Hudson M, Suissa S: Anti-rheumatic drug use and risk of hospitalization for congestive heart failure in rheuma-toid arthritis. Rheumatology 2005, 44:677–680. CrossRef
- Feltelius N, Fored CM, Blomqvist P, et al.: Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanercept. Ann Rheum Dis 2005, 64:246–252. CrossRef
- Furst DE, Breedveld FC, Kalden JR, et al.: Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004. Ann Rheum Dis 2004, 63(Suppl 2):ii2-ii12. CrossRef
- Enbrel [package insert]. Thousand Oaks, CA: Amgen, Inc; 2005.
- Humira [package insert]. North Chicago, IL: Abbott Labora-tories; 2005.
- Update of tnf-alpha antagonists and cardiovascular disease in rheumatoid arthritis
Current Rheumatology Reports
Volume 7, Issue 5 , pp 395-399
- Cover Date
- Print ISSN
- Online ISSN
- Current Medicine Group
- Additional Links